CN102356090B - 组合gas疫苗和治疗方法 - Google Patents

组合gas疫苗和治疗方法 Download PDF

Info

Publication number
CN102356090B
CN102356090B CN200980142304.9A CN200980142304A CN102356090B CN 102356090 B CN102356090 B CN 102356090B CN 200980142304 A CN200980142304 A CN 200980142304A CN 102356090 B CN102356090 B CN 102356090B
Authority
CN
China
Prior art keywords
protein
composition
antigens
spy0167
spy0416
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN200980142304.9A
Other languages
English (en)
Chinese (zh)
Other versions
CN102356090A (zh
Inventor
A·曼尼蒂
S·卡波
G·本斯
G·格兰迪
I·马格里特伊若斯
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GlaxoSmithKline Biologicals SA
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novartis AG filed Critical Novartis AG
Publication of CN102356090A publication Critical patent/CN102356090A/zh
Application granted granted Critical
Publication of CN102356090B publication Critical patent/CN102356090B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/315—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Streptococcus (G), e.g. Enterococci
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/09—Lactobacillales, e.g. aerococcus, enterococcus, lactobacillus, lactococcus, streptococcus
    • A61K39/092—Streptococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/04—Drugs for disorders of the respiratory system for throat disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1275—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Streptococcus (G)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A61K2039/507—Comprising a combination of two or more separate antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Otolaryngology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN200980142304.9A 2008-09-17 2009-09-17 组合gas疫苗和治疗方法 Active CN102356090B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US9755108P 2008-09-17 2008-09-17
US61/097,551 2008-09-17
PCT/IB2009/006949 WO2010076618A1 (en) 2008-09-17 2009-09-17 Combination gas vaccines and therapeutics

Publications (2)

Publication Number Publication Date
CN102356090A CN102356090A (zh) 2012-02-15
CN102356090B true CN102356090B (zh) 2016-01-20

Family

ID=41508998

Family Applications (1)

Application Number Title Priority Date Filing Date
CN200980142304.9A Active CN102356090B (zh) 2008-09-17 2009-09-17 组合gas疫苗和治疗方法

Country Status (18)

Country Link
US (2) US20100136041A1 (enExample)
EP (1) EP2344523B1 (enExample)
JP (2) JP5680536B2 (enExample)
CN (1) CN102356090B (enExample)
AU (1) AU2009334428B2 (enExample)
BR (1) BRPI0919236A8 (enExample)
CA (1) CA2737453A1 (enExample)
DK (1) DK2344523T3 (enExample)
ES (1) ES2566740T3 (enExample)
HR (1) HRP20160306T1 (enExample)
HU (1) HUE027618T2 (enExample)
MX (1) MX2011002760A (enExample)
NZ (1) NZ591633A (enExample)
PL (1) PL2344523T3 (enExample)
SI (1) SI2344523T1 (enExample)
SM (1) SMT201600125B (enExample)
WO (1) WO2010076618A1 (enExample)
ZA (1) ZA201102005B (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0210128D0 (en) * 2002-05-02 2002-06-12 Chiron Spa Nucleic acids and proteins from streptococcus groups A & B
SMT201700275T1 (it) 2009-10-30 2017-07-18 Glaxosmithkline Biologicals Sa Purificazione di saccaridi capsulari di staphylococcus aureus tipo 5 e tipo 8
CN103239734B (zh) * 2012-02-10 2016-02-24 北京艾棣维欣生物技术有限公司 用于预防和/或治疗呼吸道合胞病毒感染的疫苗
GB201206366D0 (en) 2012-04-11 2012-05-23 Absynth Biologics Ltd Bacterial vaccine
RU2662970C2 (ru) * 2012-09-18 2018-07-31 Новартис Аг Везикулы наружной мембраны
AU2015246654B2 (en) 2014-04-15 2019-08-08 Griffith University Group A streptococcus vaccine
WO2015169773A2 (en) * 2014-05-07 2015-11-12 Glaxosmithkline Biologicals S.A. Mutants of spy0269
US10329601B2 (en) * 2015-12-28 2019-06-25 Ionian Technologies, Inc. Nicking and extension amplification reaction (NEAR) of Streptococcus species
CN112442472B (zh) * 2020-11-30 2023-05-26 四川大学华西医院 抗艰难梭菌的重组乳酸乳球菌、活载体疫苗及其制备方法
JP7601913B2 (ja) * 2021-01-19 2024-12-17 デンカ株式会社 タンパク質、溶血性連鎖球菌ワクチン、ｄｎａ、ベクター、形質転換体、タンパク質を製造する方法、バキュロウイルス、アグロバクテリウム、ラテックス粒子、キット及び抗ストレプトリジンｏ抗体の測定方法
GB202215414D0 (en) 2022-10-18 2022-11-30 Glaxosmithkline Biologicals Sa Vaccine
CN116875520B (zh) * 2023-07-12 2024-06-14 吉林农业大学 表达核糖体失活蛋白的乳酸菌及其在抗轮状病毒中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369825A3 (en) * 1988-11-18 1990-11-22 Michael A. Kehoe Streptolysin o antigen derivative, its production and uses

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5866135A (en) * 1994-04-21 1999-02-02 North American Vaccine, Inc. Group A streptococcal polysaccharide immunogenic compositions and methods
EP1648500B1 (en) * 2003-07-31 2014-07-09 Novartis Vaccines and Diagnostics, Inc. Immunogenic compositions for streptococcus pyogenes
AU2005294275B2 (en) * 2004-10-08 2012-09-13 Glaxosmithkline Biologicals S.A. Immunogenic and therapeutic compositions for Streptococcus pyogenes
AU2007348285A1 (en) * 2006-10-30 2008-09-12 Novartis Ag Immunogenic and therapeutic compositions for streptococcus pyogenes
AU2008299376B2 (en) * 2007-09-12 2013-02-28 Glaxosmithkline Biologicals S.A. GAS57 mutant antigens and GAS57 antibodies
NZ586430A (en) * 2007-12-21 2012-09-28 Novartis Ag Mutant forms of streptolysin o (slo)

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0369825A3 (en) * 1988-11-18 1990-11-22 Michael A. Kehoe Streptolysin o antigen derivative, its production and uses

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Proteomic analysis and identification of Steptococcus pyogens surface-associated proteins;Anatoly Severin et al.;《Journal Of Bacteriology》;20061201;第189卷(第5期);第1514-1522页 *

Also Published As

Publication number Publication date
PL2344523T3 (pl) 2016-09-30
US20150132337A1 (en) 2015-05-14
AU2009334428A1 (en) 2010-07-08
US20100136041A1 (en) 2010-06-03
JP5680536B2 (ja) 2015-03-04
BRPI0919236A8 (pt) 2023-01-31
CN102356090A (zh) 2012-02-15
BRPI0919236A2 (pt) 2015-12-15
EP2344523B1 (en) 2016-02-10
SMT201600125B (it) 2016-07-01
JP2015038156A (ja) 2015-02-26
SI2344523T1 (sl) 2016-06-30
CA2737453A1 (en) 2010-07-08
WO2010076618A1 (en) 2010-07-08
DK2344523T3 (da) 2016-04-18
NZ591633A (en) 2012-10-26
ZA201102005B (en) 2016-09-28
HRP20160306T1 (hr) 2016-04-22
HUE027618T2 (en) 2016-11-28
MX2011002760A (es) 2011-06-16
JP2012502969A (ja) 2012-02-02
AU2009334428B2 (en) 2014-02-20
EP2344523A1 (en) 2011-07-20
ES2566740T3 (es) 2016-04-15

Similar Documents

Publication Publication Date Title
CN102356090B (zh) 组合gas疫苗和治疗方法
EP2537857B1 (en) Mutant forms of streptolysin O
US9102741B2 (en) GAS57 mutant antigens and GAS57 antibodies
AU2013203022B2 (en) GAS57 mutant antigens and GAS57 antibodies
AU2013203063A1 (en) Combination gas vaccines and therapeutics

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
C53 Correction of patent of invention or patent application
CB02 Change of applicant information

Address after: Basel

Applicant after: Novartis Ag

Address before: Basel

Applicant before: Novartis Vaccines & Diagnostic

COR Change of bibliographic data

Free format text: CORRECT: APPLICANT; FROM: NOVARTIS VACCINES + DIAGNOSTIC TO: NOVARTIS CO., LTD.

C14 Grant of patent or utility model
GR01 Patent grant
TR01 Transfer of patent right

Effective date of registration: 20170801

Address after: Belgium Sutter Rixon

Patentee after: Glazo Smithkline Beecham Biologicals S. A.

Address before: Basel

Patentee before: Novartis Ag

TR01 Transfer of patent right